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Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α
and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary
inflammatory mediators, including prostaglandins, cytokines, and chemokines. IL-1α is
constitutively present in endothelial and epithelial cells, whereas IL-1β is inducible in
myeloid cells and released following cleavage by caspase-1. Over the past 30 years,
IL-1-mediated inflammation has been established in a broad spectrum of diseases,
ranging from rare autoinflammatory diseases to common conditions such as gout
and rheumatoid arthritis (RA), type 2 diabetes, atherosclerosis, and acute myocardial
infarction. Blocking IL-1 entered the clinical arena with anakinra, the recombinant form
of the naturally occurring IL-1 receptor antagonist (IL-1Ra); IL-1Ra prevents the binding
of IL-1α as well as IL-1β to IL-1R1. Quenching IL-1-mediated inflammation prevents
the detrimental consequences of tissue damage and organ dysfunction. Although
anakinra is presently approved for the treatment of RA and cryopyrin-associated periodic
syndromes, off-label use of anakinra far exceeds its approved indications. Dosing of
100 mg of anakinra subcutaneously provides clinically evident benefits within days and
for some diseases, anakinra has been used daily for over 12 years. Compared to
other biologics, anakinra has an unparalleled record of safety: opportunistic infections,
particularly Mycobacterium tuberculosis, are rare even in populations at risk for
reactivation of latent infections. Because of this excellent safety profile and relative short
duration of action, anakinra can also be used as a diagnostic tool for undefined diseases
mediated by IL-1. Although anakinra is presently in clinical trials to treat cancer, this
review focuses on anakinra treatment of acute as well as chronic inflammatory diseases.
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INTRODUCTION
Historical Background of IL-1 and IL-1Ra
The history of interleukin 1 (IL-1) dates back to the purification of the endogenous fever-producing
protein called leukocytic pyrogen, as reviewed in Dinarello (2015). During the purification of
the leukocytic pyrogen, two fever-inducing proteins were observed with different molecular
weights and distinct isoelectric points. Specifically, human blood monocytes produced both a high
(35 kDa) as well as a low (15 kDa) molecular weight leukocytic pyrogen (Dinarello et al., 1974),
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with two distinct isoelectric points at 5.1 and 6.8, respectively
(Dinarello et al., 1974). Murphy et al. (1981) also reported two
leukocytic pyrogens, with isoelectric focusing points of 5.1 and
7.0 from rabbit cells. The specific biologic activity of purified
human leukocytic pyrogen was first reported in 1977 as the
induction of fever in rabbits at 10 ng/kg (Dinarello et al., 1977).
Thus, the in vivo potency of IL-1 was established in 1977 and later
confirmed in animals and humans with recombinant IL-1β. In
1979, based on the ability of purified human leukocytic pyrogen
to enhance T-cell proliferation in response to antigen recognition,
the name “leukocytic pyrogen,” or “lymphocyte activation factor”
was replaced with the current nomenclature “IL-1” (Rosenwasser
et al., 1979). The 1984 cDNA cloning of IL-1β in humans (Auron
et al., 1984) and IL-1α in mice (Lomedico et al., 1984) univocally
established that there were in fact two distinct genes coding for
IL-1. Looking back today, the higher molecular weight fever-
producing molecule was likely the IL-1α precursor, which unlike
the IL-1β precursor is biologically active without processing. In
contrast, the IL-1β precursor requires processing and proteolytic
cleavage in order to generate the lower molecular weight and
biologically active IL-1β.
Interleukin-1β exerts clinically marked pro-inflammatory
effects at very low concentrations and correlations of circulating
levels of IL-1β with disease severity is often not possible due
to the limited sensitivity of immunoassays. Instead, human
plasma has been assayed for IL-1 bioactivity by enhancement
of PHA-induced proliferation of mouse thymocytes in vitro.
This assay was reliable in that indirect readouts of IL-1
activity were found in plasma samples of subjects with
endotoxemia and in women during the menstrual cycle
(Cannon and Dinarello, 1985). The bioassay for IL-1 required
chromatographic separation of each plasma sample in order to
remove inhibitory proteins present in the plasma. Specifically,
plasma from healthy human subjects was obtained before and
after intravenous inoculum of a low dose of endotoxin. Before
the administration of the endotoxin, the plasma fractions had no
effect on thymocyte proliferation; however, 4 h after endotoxin
administration, at the peak of the fever, fractions suppressed
thymocyte proliferation. Thus, there was an endotoxin-inducible
suppressor “factor” specifically inhibiting IL-1-mediated
thymocyte proliferation in the circulation (Dinarello et al.,
1981).
Subsequent to this observation, others reported the presence
of a “specific” inhibitor of IL-1 bioactivity in supernatants of
human monocytes (Arend et al., 1985) and in the serum and
urine of children with systemic juvenile arthritis (Prieur et al.,
1987). In 1987, this “IL-1 inhibitor” isolated from the urine was
shown to prevent binding of IL-1 to cells (Seckinger et al., 1987),
thus providing evidence for its mechanism of action. The IL-1
inhibitor was purified in 1990 (Hannum et al., 1990); the cDNA
sequence first reported that same year (Eisenberg et al., 1990)
and the term IL-1 receptor antagonist (IL-1Ra) was used for
the first time in that report. Following the cDNA cloning of IL-
1Ra, a radioimmunoassay for IL-1Ra was developed and used
to assay the plasma samples from subjects during experimental
endotoxemia. Endogenous IL-1Ra is found at very low levels
in the circulation of healthy subjects (less than 200 rpg/mL),
but levels steeply rise to a mean level of 1435 pg/mL 2 h after
the infusion of endotoxin, and to top levels of 6400 pg/mL
at the peak of the fever 4 h after infusion of endotoxin
(Granowitz et al., 1991). Of note, IL-1β levels reached peak
levels of only 20 pg/mL in the same samples. In that study,
the kinetics of IL-1Ra matched the induction of the specific
suppressor of IL-1-mediated thymocyte proliferation reported
during experimental endotoxemia in 1981. In addition, the study
also revealed that there was a molar excess of at least 100-
fold IL-1Ra over IL-1β. It was not until the reports of subjects
with a genetic deletion of IL-1Ra that the critical function
of this endogenous inhibitor, which naturally suppresses IL-1
mediated inflammation, was fully revealed (Aksentijevich et al.,
2009).
Synthesis and Release of IL-1β
Interleukin-1β is not produced or detectable with standard
immunoassays in healthy tissues; rather, IL-1β is mainly
produced by inflammatory cells of the myeloid compartment:
blood monocytes, tissue macrophages, and dendritic cells.
Figure 1 summarizes the mechanisms of IL-1 activation and
signaling.
Production is stimulated by exogenous Toll-like receptor
(TLR) agonists or by endogenous cytokines such as TNFα
(Dinarello et al., 1987). IL-1α and IL-1β induce themselves.
This self-sustained induction of IL-1 is a key mechanism of
autoinflammation. In order to prevent unwanted release and
runaway inflammation, IL-1β is synthesized as an inactive
precursor, whose activation is contingent on proteolytic cleavage
by caspase-1, an intracellular cysteine protease. In turn, activation
of caspase-1 requires the oligomerization and assembly of the
“inflammasome,” a complex of intracellular proteins (Martinon
et al., 2009). Once activated, caspase-1 cleaves the N-terminal
amino acid of the inactive IL-1β precursor, thus enabling the
release of the processed, biologically active form of this cytokine.
Assembly and activation of the inflammasome thereby represents
a critical safety mechanism preventing deregulated release of
IL-1β. Unrestricted activation of caspase-1 and secretion of
IL-1β lead to systemic and multi-organ sterile inflammation,
which characterizes autoinflammatory diseases (Hoffman and
Wanderer, 2011).
Anakinra Reveals the Nature of
Autoinflammatory Disorders
The term IL-1 is often used without distinguishing between
the two gene products, IL-1α and IL-1β. This is because both
cytokines bind to the same signaling receptor, the IL-1 receptor
1 (IL-1R1), and hence there is no significant difference between
the biological activities of either cytokine. IL-1Ra, also an
endogenous member of the IL-1 family, binds to the IL-1R1
and therefore blocks the activity of both IL-1α and IL-1β.
A recombinant form of IL-1Ra (anakinra) is used to treat a
broad variety of diseases, ranging from common conditions such
as rheumatoid arthritis (RA), gout, and idiopathic pericarditis,
to rare hereditary diseases. Specific mutations in diseases such
as familial Mediterranean fever (FMF) and cryopyrin-associated
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FIGURE 1 | Production and release of IL-1, signaling and inhibition of IL-1 activities. (1) The IL-1β precursor is induced in monocytes/macrophages following
engagement of pattern recognition receptors (PRR) or by pro-inflammatory cytokines, including IL-1α and IL-1β. IL-1β is synthesized as an inactive precursor
(pro-IL-1β). Release of biologically active IL-1β takes place by enzymatic cleavage of the precursor protein by caspase-1. Activation of caspase-1 requires induction
of the NLRP3 inflammasome. (2) Neutrophils release the IL-1β precursor into the extracellular space where it is cleaved to active IL-1β by neutrophil-derived
proteases. (3) The IL-1α precursor is constitutively present in most epithelial cells and is fully active. Upon cell necrosis, the intracellular IL-1α precursor is released
and acts as an alarmin. (4) Both IL-1α and IL-1β bind to IL-1 receptor type 1 (IL-1R1), which is followed by recruitment of the co-receptor IL-1R3 (formerly termed
IL-1 receptor accessory protein, IL-1RAcP). The heterotrimer results in the approximation of the intracellular TIR domains of IL-1R1 and IL-1R3. MyD88, IL-1
receptor-associated kinase 4 (IRAK4), and NFκB are phosphorylated. NFκB induces transcription of pro-inflammatory genes. Mechanisms physiologically
counteracting the activity of IL-1α and IL-1β include: (5) The IL-1 receptor antagonist (IL-1Ra, green) binds IL-1R1 and prevents binding of IL-1α and IL-1β, thereby
resulting in no signal. (6) The IL-1 receptor type 2 (IL-1R2) preferentially binds IL-1SS, but lacking a cytoplasmic domain, acts as a decoy receptor and there is no
signal. (7) Soluble IL-1R2 (extracellular domain only) binds IL-1β and forms a complex with soluble IL-1R3, resulting in neutralization of IL-1β.
periodic syndrome (CAPS) result in deregulated release of
active IL-1β, which is clinically manifested as periodic fevers
with systemic and local inflammation. These diseases do not
involve T-lymphocytes, which characteristically represent the
effector cells of every autoimmune disease, nor autoantibodies.
Therefore, these diseases are not considered autoimmune
diseases, but rather termed “autoinflammatory” syndromes.
In autoinflammatory diseases, the effector cell is a myeloid
cell, characteristically a monocyte or macrophage (Dinarello
et al., 2012). The central role of IL-1 in the pathogenesis of
autoinflammation is well established. Monocytes from patients
with autoinflammatory diseases release more IL-1β, but not
TNFα, compared to healthy persons (Pascual et al., 2005;
Goldbach-Mansky et al., 2006; Gattorno et al., 2007).
Autoinflammatory diseases can be regarded as a “natural
experiment”, which reveals the clinical and pathologic
consequences of deregulated IL-1-mediated inflammation
in humans. Lessons from autoinflammatory diseases extend
and apply beyond this group of rare conditions: deregulated
activation of the myeloid compartment and IL-1 also mediate
several common diseases, which can also be classified as
autoinflammatory disorders (i.e., gout, pericarditis), or at least
include autoinflammation as part of disease pathogenesis (i.e.,
heart failure, diabetes, myocarditis; Cavalli et al., 2016a; Hayashi
et al., 2016; Netea et al., 2017). Because of the safety and rapid
onset of action, IL-1 inhibition with anakinra can be used as a
diagnostic as well as a treatment tool for patients with undefined
signs or symptoms of autoinflammation (Harrison et al., 2016).
Figure 2 illustrates the broad variety of organ manifestations
of IL-1-mediated inflammation, which can be treated with
anakinra.
AUTOINFLAMMATORY DISEASES
Autoinflammatory diseases are a spectrum of hereditary or
multifactorial conditions variably manifested with clinical and
hematologic features of IL-1-mediated inflammation: these
include fever, fatigue, myalgia, arthralgia, arthritis, serositis,
gastrointestinal involvement, skin rashes, and multi-organ
involvement, often accompanied by neutrophilia and elevated
inflammatory markers. Most autoinflammatory diseases occur in
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FIGURE 2 | Clinical manifestations of IL-1-mediated inflammation, which are reversible upon treatment with anakinra.
recurrent flares. In some autoinflammatory diseases, causative
mutations resulting in deregulated release of active IL-1 have
been identified. However, in other autoinflammatory diseases,
a specific mutation to account for excessive IL-1 activity has
not yet been determined; in some cases, defects in regulatory
molecules counteracting the biologic activity of IL-1 can be
determined, or postulated (Aksentijevich et al., 2009; Cavalli
et al., 2016b; Cavalli et al., 2017c,d; Ballak et al., 2018; Cavalli
and Dinarello, 2018). Regardless of the underlying mechanisms,
disease manifestations are characteristically controlled by IL-
1 blockade with anakinra; as different pharmacokinetics result
in more prolonged duration of action, neutralizing antibodies
directed against IL-1β (canakinumab) represent an alternative in
patients enduring frequent disease flares. The efficacy of anakinra
in the treatment of these conditions is discussed below; more
detailed lists of hereditary as well as non-hereditary inflammatory
diseases responsive to anakinra treatment are provided in
Tables 1, 2.
Cryopyrin-Associated Periodic
Syndromes (CAPS)
The term “CAPS” encompasses a spectrum of three
hereditary diseases: familial cold autoinflammatory syndrome
(FCAS), Muckle–Wells syndrome (MWS), and neonatal
onset multi-inflammatory diseases (NOMID). The clinical
phenotypes of FCAS, MWS, and NOMID are characterized
by escalating severity, ranging from self-limited episodes of
fever, myalgia, and skin rash (FCAS), to chronic systemic
and organ-specific inflammation with major complications
(NOMID). The pathologic hallmark of CAPS is the presence
of activating mutations in the NLRP3 inflammasome,
which result in induction of caspase 1 and deregulated
release of IL-1β (Agostini et al., 2004; Goldbach-Mansky
et al., 2006; Gattorno et al., 2007). Anakinra, as well as
other IL-1-blocking agents, is dramatically effective in
the treatment of CAPS (reviewed in Cavalli and Dinarello,
2015).
Familial Mediterranean Fever (FMF) and
Amyloidosis
Familial Mediterranean fever is a prototypical autoinflammatory
disease characterized by recurrent bouts of fever, rash, and
serositis, which are typically self-limited in 3–5 days. The
disease is autosomal recessive, and determined by mutations
in the MEFV gene, encoding for pyrin, a protein involved in
inflammasome formation, activation of caspase 1, and release of
active IL-1β (Chae et al., 2006). Colchicine is the cornerstone of
treatment for FMF, but is ineffective in some patients. Patients
refractory to conventional treatment are successfully treated with
anakinra (Meinzer et al., 2011; Ozen et al., 2011).
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TABLE 1 | Anakinra for hereditary systemic inflammatory diseases.
Familial Mediterranean fever (FMF; Meinzer et al., 2011; Ozen et al., 2011)
CAPS (Hawkins et al., 2003; Goldbach-Mansky et al., 2006; Kullenberg
et al., 2016)
TRAPS (Simon et al., 2004; Gattorno et al., 2008a)
PAPA (Dierselhuis et al., 2005; Brenner et al., 2009; Braun-Falco et al.,
2011; Schellevis et al., 2011)
PASH (Braun-Falco et al., 2011; Marzano et al., 2013)
DIRA (Aksentijevich et al., 2009; Reddy et al., 2009; Sakran et al., 2013)
Blau syndrome/granulomatous arthritis (Arostegui et al., 2007; Punzi et al.,
2011)
Mevalonate kinase deficiency/hyper-IgD syndrome (Ruiz Gomez et al.,
2012)
Majeed syndrome (Herlin et al., 2013)
NLRP12 autoinflammatory syndrome (Jeru, 2011)
Interleukin-1 induces serum amyloid A (SAA), which is
thereby commonly elevated in several chronic inflammatory
diseases. Progressive deposition of amyloid fibrils in tissues
results in amyloidosis, a condition leading to severe organ
dysfunction, including lethal kidney or heart failure, which
are major causes of death in untreated FMF and CAPS.
However, effective dampening of chronic inflammation with IL-1
blockers prevents progression to amyloidosis and organ failure
(Moser et al., 2009; Ait-Abdesselam et al., 2011; Ozen et al.,
2011; Stankovic Stojanovic et al., 2012). Intriguingly, amyloid
deposition leading to organ dysfunction is also a feature of other,
multifactorial conditions in which IL-1 has emerged as a pivotal
pathologic mediator: amyloidosis of insulin-producing islets and
brain characterizes T2D and Alzheimer disease, respectively (Tan
et al., 2007; Masters et al., 2010). In both conditions, IL-1
blockade may represent a suitable therapeutic strategy to hinder
disease progression.
TNF-Receptor Associated Periodic
Syndrome (TRAPS)
TNF-receptor associated periodic syndrome (TRAPS) is an
autosomal dominant disease caused by mutations in TNF-
receptor type 1 (McDermott et al., 1999), and clinically
manifested as recurrent flares of fever, rash, and serositis.
A deficiency of soluble TNFα receptors, which neutralizes
circulating TNFα, was postulated. Nevertheless, clinical response
to TNFα inhibition is only partial, and even absent in many
patients. Current understanding rather postulates a deficit in
membrane translocation of TNF-receptor type 1, which leads
to an unfolded protein response, cellular stress, and consequent
release of IL-1β (Cantarini et al., 2012b). This view is also
substantiated by clinical efficacy of anakinra, even in refractory
cases (Simon et al., 2004; Gattorno et al., 2008a).
Hyper-IgD Syndrome (HIDS)
Also known as mevalonate kinase deficiency, Hyper-IgD
syndrome (HIDS) is an autosomal recessive autoinflammatory
disorder characterized by recurrent fever, myalgia, skin rash,
and lymphadenopathy. Episodes usually last 4–6 days and can
be triggered by infections. Multiple intracellular pathways link
TABLE 2 | Anakinra for systemic and local inflammatory diseases.
Schnitzler syndrome (Ryan et al., 2008)
Behçet disease (Cantarini et al., 2015b)
Secondary amyloidosis (Moser et al., 2009; Ait-Abdesselam et al., 2011;
Stankovic Stojanovic et al., 2012)
Henoch–Schonlein purpura (Boyer et al., 2011)
Idiopathic recurrent pericarditis (Picco et al., 2009; Brucato et al., 2016)
Systemic-onset juvenile idiopathic arthritis (Gattorno et al., 2008b; Vastert
et al., 2014)
Adult-onset still disease (Fitzgerald et al., 2005; Cavalli et al., 2015b;
Colafrancesco et al., 2017)
Macrophage activation syndrome (Gattorno et al., 2008b; Miettunen et al.,
2012; Rajasekaran et al., 2014; Vastert et al., 2014; Sonmez et al., 2018)
Sweet’s syndrome/neutrophilic dermatoses (Delluc et al., 2008; Kluger
et al., 2011; Pazyar et al., 2012; Belani et al., 2013)
Neutrophilic panniculitis (Behrens et al., 2006; Aronson and Worobec,
2010; Lipsker et al., 2010)
Erdheim–Chester/histiocytoses (Aouba et al., 2010; Diamond et al., 2016;
Tomelleri et al., 2018)
SAPHO (Colina et al., 2010; Eleftheriou et al., 2011; Wendling et al., 2012)
PFAPA (Stojanov et al., 2011; Cantarini et al., 2012a)
Multicentric Castleman disease (Galeotti et al., 2008)
Jessner–Kanof disease (Sparsa et al., 2012)
Primary Sjögren syndrome fatigue (Norheim et al., 2012)
Kawasaki disease (Cohen et al., 2012)
Colitis in chronic granulomatous disease (van de Veerdonk et al., 2011)
Hidradenitis suppurativa (Tzanetakou et al., 2016)
Autoimmune inner ear disease (Vambutas et al., 2014)
mevalonate kinase deficiency with deregulated release of IL-
1 production (Stoffels and Simon, 2011). Consistently, IL-1
inhibitors effectively reduce the frequency and severity of the
attacks of HIDS (Bodar et al., 2011).
Adult Onset Still’s Disease (AOSD) and
Systemic Onset Juvenile Idiopathic
Arthritis (SOJIA)
Adult onset Still’s disease (AOSD) is a rare, systemic
inflammatory syndrome characterized by arthritis, fever,
rash, multi-organ inflammation, and strikingly elevated serum
inflammatory indexes, particularly ferritin. Consistent with
observations that the NLRP3 inflammasome is highly expressed
and activated in AOSD (Hsieh et al., 2017), IL-1β blockade,
even with anakinra as monotherapy, represents the mainstay of
biologic treatment and effectively controls disease manifestations
(Fitzgerald et al., 2005; Naumann et al., 2010; Cavalli et al., 2015b;
Colafrancesco et al., 2017; Junge et al., 2017).
Rather than being distinct clinical entities, SOJIA and AOSD
are considered different manifestations of the same disease,
occurring in infancy and adulthood, respectively. The efficacy
of anakinra in SOJIA is thereby not unexpected, even in
patients refractory to treatment with steroids, methotrexate,
or TNFα blockers (Quartier et al., 2011). Both in AOSD
and SOJIA, two distinct clinical phenotypes can be identified.
One is characterized by rampant systemic inflammation with
neutrophilia and elevated acute phase proteins, and by a lower
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number of inflamed joints: this form is dramatically and
characteristically responsive to IL-1 blockade (Gattorno et al.,
2008b). On the other hand, a clinical phenotype characterized by
more severe arthritis and limited systemic inflammation may not
respond as brilliantly to IL-1 inhibition.
Of note, treatment of SOJIA poses challenges beyond the
mere achievement of disease control, related to the problematic
use of immunosuppressive therapies in a pediatric population.
For instance, steroid treatment is associated with growth
retardation. In this scenario, IL-1 inhibition may be particularly
advantageous, as treatment with anakinra or canakinumab results
in reduced glucocorticoid dosing and catch-up growth (Ruperto
et al., 2012). A prospective study evaluated anakinra (2 mg/kg)
as a first-line drug in 20 children with new-onset SOJIA, and
documented a near complete clinical response within 3 months of
treatment initiation, which was sustained at 32 months of follow-
up and allowed most patients to discontinue treatment (Vastert
et al., 2014).
Schnitzler Syndrome (SchS)
Schnitzler syndrome (SchS) is characterized by chronic urticarial,
fever, and development of hematopoietic malignancies,
particularly Waldenström macroglobulinemia. The SchS
International Registry reports nearly 100% efficacy with anakinra
treatment, which leads to clinical improvement within hours
and remission within days (Ryan et al., 2008). Remission
upon treatment is durable, but disease flares may occur at
discontinuation (Mertens and Singh, 2009a). The efficacy of
anakinra is SchS is so distinctive that diagnosis should be
reconsidered in the event of treatment failure. Canakinumab
is also highly effective in SchS (de Koning et al., 2013). Of
note, a recent study reported that some patients with SchS have
myeloid-lineage restricted somatic mosaicism for mutations
in NLRP3, which is associated with increased IL-1 activity in
monocytes. This phenomenon likely explains the late onset of
disease in some patients (de Koning et al., 2015).
ANAKINRA FOR THE HEART
The central role of IL-1-mediated inflammation is established in
the pathogenesis of atherosclerosis, ischemia-reperfusion injury,
cardiac remodeling, and myocardial infarction (Pomerantz et al.,
2001; Kamari et al., 2007; Duewell et al., 2010; Ridker et al., 2017).
The beneficial effects of IL-1 blockade with anakinra in heart
disease are discussed hereby, and summarized in Table 3.
Atherosclerosis
Chronic inflammation is central to the pathogenesis of
atherosclerosis (Libby et al., 2002), and IL-1 specifically promotes
the formation, growth, and rupture of vascular atherosclerotic
plaques, which account for ischemic cardiovascular
complications (Peiro et al., 2017; Buckley and Abbate, 2018).
Both IL-1β and IL-1α are highly expressed in atherosclerotic
lesions, and promote recruitment of leukocytes by inducing
endothelial cells to express adhesion molecules; in addition,
IL-1 impairs vasodilation while inducing oxidative stress and
TABLE 3 | Anakinra for the heart.
↓ Inflammation in acute myocardial infarction
↑ Exercise performance in heart failure
↑ Oxygen consumption in heart failure
↓ Systemic inflammation in heart failure
↓ Hospitalizations for recurrent acute heart failure
↓ Pain and inflammation in recurrent idiopathic pericarditis
↑ Function in acute myocarditis and heart failure
↑ Exercise tolerance in heart failure associated with rheumatoid arthritis
pro-coagulant mediators (Peiro et al., 2017). Experimental pre-
clinical evidence shows that many of these effects can be reversed
by IL-1β inhibition, thus pointing at selective pharmacological
blockade as a suitable treatment strategy to dampen progression
of atherosclerotic lesions (Peiro et al., 2017). Although the ability
of anakinra or other IL-1β blocking drugs to prevent progression
of atherosclerosis in humans has not been specifically studied, IL-
1 inhibition with anakinra and canakinumab proved beneficial in
the treatment of major clinical complications of atherosclerosis,
such as acute myocardial infarction and ischemic cardiovascular
disease, as detailed in the following sections of this review.
Acute Myocardial Infarction
The first studies of anakinra in acute ischemic heart disease
involved patients who had suffered a ST-elevated myocardial
infarction (STEMI; Abbate et al., 2010, 2013). In these studies,
anakinra 100 mg daily was administered subcutaneously for 2
weeks, following stent placement and in addition to optimal
standard of care. Seventy-two hours after the acute event,
despite optimal standard of care, inflammation develops due to
myocardial ischemia; CRP reaches peak levels, which correlate
with the size of the infarcted area. Anakinra treatment resulted
in a significant reduction in CRP levels (Abbate et al., 2013), thus
reducing the progressive inflammatory response and myocardial
damage. Infiltration of neutrophils and monocytes into the area
surrounding the ischemic tissue contributes to further damage,
which is significantly reduced by anakinra treatment in animal
studies (Toldo et al., 2013). Twelve weeks following myocardial
infarction, heart function of patients was evaluated as residual left
ventricular ejection fraction. Compared to the placebo-treated
group, anakinra-treated patients exhibited improved functional
status, but did not reach statistical significance (Abbate et al.,
2013). A second trial was performed with 30 patients (Abbate
et al., 2013). Again, anakinra significantly reduced CRP levels 72 h
after myocardial infarction; after 10–14 weeks, this reduction in
CRP correlated with a reduction in left ventricular end-systolic
volume (Abbate et al., 2013). Patients treated with anakinra
exhibited an overall reduction in the development of heart failure
(New York Heart Association Grade III and IV) compared to
placebo-treated patients (Abbate et al., 2013).
Subsequent studies confirmed that anakinra treatment
effectively dampens inflammation associated with myocardial
infarction. Anakinra treatment was started after standard of care
for the acute event and protracted for 14 days in 182 patients
with non-STEMI myocardial infarction (Morton et al., 2015).
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For 7 days following the acute event, a significant reduction in
CPR was observed in patients receiving anakinra compared to
placebo (21 compared to 43 mg day/L); levels rose again 16 days
after cessation of anakinra (Morton et al., 2015).
In the massive Canakinumab Anti-inflammatory Thrombosis
Outcomes Study (CANTOS), 10,061 patients with prior
myocardial infarction and evidence of systemic inflammation
as determined by elevated serum CRP were randomized to
receive either placebo or canakinumab (50, 150, or 300 mg every
3 months). At 48 months, patients treated with canakinumab
150 mg exhibited a 15% reduction in the primary endpoint
of recurrent non-fatal myocardial infarction and non-fatal
stroke, or cardiovascular death, as well as reduced need for
coronary revascularization, compared to placebo (Ridker et al.,
2017). These definitive results indicate that IL-1β blockade with
canakinumab in patients with atherosclerotic cardiovascular
disease can prevent recurrent cardiovascular events. Of note, this
benefit was closely related to suppression of inflammation, as
patients exhibiting the greatest reduction in CRP had improved
survival upon treatment (Ridker et al., 2018).
Heart Failure
Several years ago, ex vivo studies with human atrial heart strips
revealed that IL-1β suppresses cardiac contractility, even at
picomolar concentrations (Cain et al., 1999). In recent years,
various studies examined the effects of anakinra on heart failure
with poor exercise tolerance and signs of systemic inflammation.
For example, mice treated with a single dose of recombinant
human IL-1β have a 76% reduction in response to isoproterenol
and a 32% reduction in left ventricular function. In a clinical
trial, seven patients with heart failure and markers of systemic
inflammation despite standard of care treatment received 100 mg
of anakinra daily for 14 days. Compared to baseline, treatment
with anakinra was associated with a statistically significant
improvement in oxygen consumption, a marker of exercise
capability (Van Tassell et al., 2012). This study first established
a role for anakinra treatment in patients with refractory heart
failure.
Besides impaired left ventricular contractility, heart failure
with preserved ejection fraction can also occur and be associated
with reduced exercise tolerance. When patients with this
condition were treated with anakinra 100 mg daily for 14
days in a double-blind, randomized, placebo controlled study,
patients receiving treatment exhibited a significant increase in
oxygen consumption of 1.2 mL/kg/min and a concomitant 74%
reduction in CRP.
Patients with acute, decompensated heart failure often exhibit
signs of systemic inflammation. Thirty patients with acute
decompensated heart failure, ejection fraction less than 40%, and
elevated CRP were randomized to receive either anakinra or
placebo (Van Tassell et al., 2016). Upon entering the trial, patients
received either 100 mg anakinra or placebo twice daily for 3 days
followed by 11 days of once daily dosing. Three days into the
trial, CRP decreased by 61% in the anakinra group compared to
the placebo-treated group (Van Tassell et al., 2016). Although the
study was not powered to determine a clinical benefit, it showed
that IL-1β inhibition with IL-1 receptor blockade reduced the
systemic inflammation associated with acute heart failure.
In all these trials on heart failure, patients received anakinra
for only 14 days. Although clinical and objective data indicate
a functional improvement as well as reduced inflammation
already with short-term treatment, it is likely that a prolonged
course of anakinra would result in a more marked benefit.
For example, patients hospitalized with an episode of acute
decompensated heart failure are at high risk for repeated
hospitalizations due to recurrent episodes. Therefore, a trial was
conducted comparing two different treatment durations (2 versus
12 weeks) of anakinra 100 mg daily in patients discharged from
the hospital following an episode of acute decompensated heart
failure. In this study, patients treated with 12 weeks of anakinra
had reduced hospital readmission rates and improved aerobic
capacity, oxygen consumption, and quality of life compared to
patients receiving either placebo or 2 weeks of anakinra (Van
Tassell et al., 2017). Of note, patients receiving anakinra for RA
exhibited improved cardiac contractility, even within 3 h of a
single administration (Ikonomidis et al., 2008).
Idiopathic Recurrent Pericarditis
Pericarditis is an autoinflammatory manifestation, often
encountered as part of the clinical spectrum of inherited
autoinflammatory disorders such as TRAPS, FMF, and CAPS,
and successfully treated with anakinra (Cantarini et al., 2010;
Kuemmerle-Deschner et al., 2011b). Patients with AOSD also
can have bouts of pericarditis (Gerfaud-Valentin et al., 2014) and
respond to anakinra (Cavalli et al., 2015b; Colafrancesco et al.,
2017).
However, inflammation of pericardium can occur as
an isolated, recurrent manifestation with no clear genetic
predisposition (idiopathic recurrent pericarditis), which often
develops after a viral illness. Anakinra is highly effective in
treating these patients and provides a rapid and sustained
reduction in pain, particularly in patients refractory to
conventional treatment with colchicine (Scott et al., 2011;
Imazio, 2014; Brucato et al., 2016). Treating pericarditis with
etanercept or infliximab has not been successful (Ambrose and
O’Connell, 2007; Devasahayam et al., 2012).
Myocarditis and Dilated Cardiomyopathy
Clinical observations indicate a central role of IL-1 in the
pathogenesis of cardiac inflammation. For example, myocardial
involvement is part of the clinical spectrum of inflammatory
(Cavalli et al., 2013b, 2014; Campochiaro et al., 2015) or
autoinflammatory diseases (Lopetuso et al., 2013; van de
Veerdonk and Netea, 2013), such as AOSD or SOJIA, which
are characteristically mediated by IL-1. IL-1 blockade is highly
effective in these conditions (Cavalli and Dinarello, 2015), as
exemplified by several published cases of myocarditis associated
with SoJIA and AOSD and promptly controlled by anakinra
(Raffeiner et al., 2011; Movva et al., 2013; Choi et al., 2014; Cavalli
et al., 2015b). However, there is emerging evidence that anakinra
can be effective in the treatment of fulminant myocarditis
irrespective of the initiating trigger or underlying condition
(Raffeiner et al., 2011; Cavalli et al., 2016c, 2017b; De Luca
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et al., 2018b). In patients with myocarditis-associated acute heart
failure, beneficial effects of anakinra on myocardial contractile
function are particularly striking, and generally consistent with
the observed benefit in patients with heart failure. It remains
to be determined whether anakinra would increase myocardial
function in non-acute myocarditis as it does in the acute
condition. Blocking TNFα in myocarditis is contraindicated.
There are case reports of anakinra treatment for myocarditis in
patients non-responsive to anti-IL-6 (Waghmare et al., 2015).
A recent report described the efficacy of anakinra in a
patient with dilated cardiomyopathy, a severe, irreversible heart
disease characterized by left ventricular systolic dysfunction
and dilation, which are not explained by abnormal loading
or coronary artery disease. It is likely that several etiologic
types of myocardial damage confluence in this common end-
stage condition, which is histologically characterized by loss
of contractile tissue, remodeling, and fibrosis. In the patient
described in this study, histologic analyses of heart specimens
had revealed subtle inflammation: treatment with IL-1 inhibition
was thereby started, and led to a prompt clinical improvement
in contractile function and arrhythmic burden (De Luca et al.,
2018a). These results point at a possible role of low-grade chronic
inflammation in the pathogenesis of dilated cardiomyopathy.
DIABETES AND METABOLIC
SYNDROME
Interleukin-1-mediated inflammation plays a critical role in the
progressive loss of β cells, which characterizes progression from
insulin resistance to T2D (van Asseldonk et al., 2011). Specifically,
IL-1β gene expression is dramatically elevated in β-cells of
T2D patients compared to controls (Donath and Shoelson,
2011), whereas IL-1Ra levels are locally reduced and insufficient
to protect β-cells from inflammation-mediated damage (Boni-
Schnetzler et al., 2018).
Mechanistically, high glucose concentrations trigger β cells to
produce IL-1β (Maedler et al., 2002), which in turn contributes
to β-cell loss by promoting deposition of amyloid (Masters
et al., 2010). These pivotal observations delineated a new
concept of T2D as a chronic inflammatory disease, in which
IL-1-driven inflammation results in progressive loss of β cell
function (Donath and Shoelson, 2011), and provided rationale
for testing anakinra in T2D. In a randomized trial, treatment
with anakinra for 13 weeks led to improved insulin production
and glycemic control. Reduction in IL-1-mediated inflammation
was confirmed by decreased levels of CRP and IL-6 (Larsen
et al., 2007), and likely particularly relevant and sustained
at the islet level, as treatment responders required 66% less
insulin to maintain glycemic control in the 39 weeks following
discontinuation (Larsen et al., 2009). This pilot study led to
subsequent, large trials of anti-IL-1β monoclonal antibodies
gevokizumab, LY2189102, and – particularly – canakinumab in
T2D, which all confirmed clinical benefits (Cavelti-Weder et al.,
2012; Rissanen et al., 2012; Sloan-Lancaster et al., 2013).
Human fat tissue is an inflammatory environment in which
infiltrating macrophages produce IL-1β (Stienstra et al., 2011).
Anakinra treatment was thereby also evaluated in non-diabetic
patients with metabolic syndrome, and was associated with a
decrease in CRP and a corresponding increase in disposition
index, thus reflecting improved β cell function (van Asseldonk
et al., 2011).
Given the association between cardiovascular disease and
T2D, the potential of IL-1 blocking agents to improve
cardiovascular health and glucose metabolism was assessed
in the large CANTOS trial, which determined that treatment
with the anti-IL-1β monoclonal antibody canakinumab reduces
re-occurrence of ischemic events in patients with prior
cardiovascular accidents (Ridker et al., 2017). The CANTOS trial
met its primary and secondary endpoints in both T2D subjects
as well as in those without diabetes. Consistent with anakinra
treatment in T2D, canakinumab reduced HbA1c during the
first 6–9 months of treatment (Everett et al., 2018). However,
after nearly 4 years of canakinumab treatment, prevention of
progression to overt T2D in subjects with impaired glucose
tolerance at enrollment was not observed and there was no
sustained improvement in glycemic control (Everett et al., 2018).
Thus, there is likely a role for IL-1α in T2D. Indeed, two studies in
recent onset T1D tested anakinra versus canakinumab. Increased
C-peptide was reported in subjects treated with anakinra but not
canakinumab (Moran et al., 2013).
JOINT DISEASES
Rheumatoid Arthritis and Associated
Comorbidities
The efficacy of anakinra treatment in RA was evaluated in
several controlled studies (Mertens and Singh, 2009b). Anakinra
monotherapy or in association with methotrexate significantly
reduced disease severity, joint space narrowing, radiographic
joint damage, and bone erosions, while also improving quality of
life (Bresnihan et al., 2004). However, other biologics, including
TNFα blockers, dominate the field of biologic treatments for
RA. No direct comparison is available between the efficacy of
IL-1 blockade and the overwhelming number of competing
biologic agents; based upon indirect comparisons, anakinra
seems moderately efficacious (Singh et al., 2010). Currently,
anakinra is mostly administered to those RA patients in whom
other biologics proved ineffective or are contraindicated, for
example, due to previous malignancy or recurrent infections. In
patients refractory to anti-TNFα therapy, anakinra was shown
to be effective in controlling disease activity (Genant et al.,
2001; Bresnihan et al., 2004; Botsios et al., 2007). Similar to
anakinra, the anti-IL-1β monoclonal antibody canakinumab
has reduced disease severity in RA patients, including those
unresponsive to anti-TNFα therapies (Alten et al., 2011);
however, unlike anakinra, long-term preservation of joint
function with canakinumab remains unstudied.
Compared to the general population, RA patients exhibit a
higher incidence of T2D and cardiovascular events (Primdahl
et al., 2013). In particular, infection and cardiovascular disease
are the leading causes of death in RA patients, whereas T2D
and metabolic syndrome are burdensome comorbidities (Kelly
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and Hamilton, 2007). An ideal treatment should thereby not
only reduce pain and prevent articular damage, but also aim at
treating associated comorbidities with minimal adverse effects.
Given the IL-1-mediated nature of these comorbidities, and the
documented favorable effects of IL-1 blockade on cardiovascular
and metabolic diseases (discussed above in the present review;
Dinarello et al., 2012), benefits of anakinra in RA may extend
beyond the mere efficacy on articular inflammation and are worth
further exploration.
Gout and Other Forms of
Crystal-Induced Arthritis
Monosodium urate crystals activate the NLRP3 inflammasome
and induce the release of active IL-1β, with a contribution of
free fatty acids, which likely account for the diet-related flares
of gout (Joosten et al., 2010). Given the prominent neutrophil
infiltration, extracellular processing by neutrophil proteases also
likely accounts for activation of IL-1β precursor in gouty joints
(Joosten et al., 2009). Traditional options for managing acute
flares include colchicine, non-steroidal anti-inflammatory drugs
(NSAIDs), and steroids. Treatment with anakinra is dramatically
effective at dampening articular inflammation (McGonagle et al.,
2007), while also resulting in prolonged periods without flares.
Of note, the short half-life and excellent safety profile makes
anakinra an ideal therapeutic option for the treatment of acute
flares of gouty arthritis, and possibly of patients with underlying
chronic kidney disease. Pyrophosphate crystal arthritis, a disease
highly reminiscent of gout, is also characteristically responsive
to anakinra (McGonagle et al., 2008; Announ et al., 2009),
as is another common crystal-induced inflammatory condition,
that is, acute calcific periarthritis of the shoulder (Zufferey
and So, 2013). In these conditions, short-course anakinra
treatment is associated with durable reduction of pain and
function impairment, and with normalization of inflammatory
indexes.
Osteoarthritis
There is clinical and experimental evidence that IL-1 is involved
in the pathogenesis of osteoarthritis. Thereby, previous studies
evaluated the efficacy of direct instillation of anakinra into
affected knee joints. Nevertheless, intra-articular injections of
anakinra in patients with knee osteoarthritis yielded limited
clinical benefit, which did not extend beyond one month
from administration (possibly due to short-term persistence of
anakinra in the joint space; Chevalier et al., 2005, 2009). Anakinra
has demonstrated some efficacy against joint pain and swelling
in erosive osteoarthritis of the hand (Bacconnier et al., 2009).
IL-1 inhibition with antibodies to the IL-1 receptor has also
been evaluated, again with only modest improvement (Cohen
et al., 2011). Recent data from the worldwide CANTOS trial
supports a role for IL-1β in osteoarthritis. Although this was
not the intent of the study, a highly significant reduction in
osteoarthritis pain and improved joint function was reported by
those treated with canakinumab compared to patients receiving
placebo (Ridker et al., 2017). Patients receiving 150 mg of
canakinumab fives times each year reported a low incidence of
osteoarthritis (1.67 per 100 person-years for placebo versus 1.12
for canakinumab, p < 0.001). Supporting evidence to a role for
IL-1β in osteoarthritis from the CANTOS database is derived
from (i) the large number of patients enrolled world-wide, (ii)
the randomized, placebo controlled nature of the trial, and (iii)
the specificity of IL-1β neutralization. The demographics of the
CANTOS population include age, high BMI, and type 2 diabetes,
each of which is characteristic of the osteoarthritis population.
Not unexpectedly, there was also a significant reduction in gouty
arthritis (Ridker et al., 2017). Although canakinumab treatment
was effective in reducing osteoarthritis, systemic treatment
with anakinra or canakinumab is an unlikely therapy for the
disease.
MULTIFACTORIAL INFLAMMATORY
CONDITIONS
Macrophage Activation Syndrome
Role of IL-1 and IL-18 in Macrophage Activation
Syndrome
Macrophage activation syndrome (MAS), also known as
hemophagocytic lympho-histiocytosis (HLH), is a rare,
life-threatening condition characterized by a severe hyper-
inflammatory state. It is clinically manifested with fever, elevated
ferritin, liver enzymes, triglycerides, and pancytopenia due to
phagocytosis of bone marrow hematopoietic precursors. Both
genetic (familial HLH) and acquired forms of MAS have been
described, the latter associated with infection with Epstein–Barr
virus, cytomegalovirus, other herpes viruses, and intracellular
bacteria, and also of various lymphomas, especially of T-cell
lineage. The incidence of MAS is underestimated, as also
suggested by new reports of MAS in patients with Ebola virus,
parasitic, and influenza infections (Kumar et al., 2014; van
der Ven et al., 2015). In addition, patients with rheumatologic
conditions, particularly SoJIA and AOSD but also systemic lupus
erythematous, Kawasaki disease (KD), or systemic vasculitis can
develop MAS (Grom, 2003; Grom et al., 2003; Grom and Mellins,
2011; Janka, 2012).
The pathogenesis of MAS is captivating increasing interest
(Schulert and Grom, 2015), and debate is ongoing as to whether
MAS is prevalently mediated by IL-1 or IL-18. In the case
of familial HLH, gene expression for IL-18 is upregulated in
circulating mononuclear cells (Ogilvie et al., 2007; Sumegi et al.,
2011), and serum levels of IL-18 are unusually elevated (Honda
et al., 2000; Emmenegger et al., 2002; Maeno et al., 2004;
Mazodier et al., 2005; Nold et al., 2010). For comparison, levels
of circulating IL-18 are below 1 ng/mL in inflammatory diseases
such as severe sepsis, but can reach a 20–30 nm/mm range
in MAS complicating systemic SoJIA (Larroche and Mouthon,
2004; Fitzgerald et al., 2005; Mazodier et al., 2005; Wada et al.,
2013). However, since an IL-18 neutralizing protein [IL-18
binding protein (IL-18BP)] is present in the circulation in health
and promptly increases during inflammation, it is critical to
determine the levels of free, biologically active IL-18 (Novick
et al., 2001). In patients with MAS, free IL-18 significantly
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correlated with clinical status and biologic markers of MAS, such
as anemia, hypertriglyceridemia, and hyperferritinemia, but also
with markers of Th1 lymphocyte or macrophage activation, such
as IFNγ and soluble receptors for IL-2 and TNFα (Mazodier
et al., 2005). A case of MAS due to a mutation in the NLRC4
inflammasome was successfully treated with IL-18BP, whereas
anakinra therapy did not effectively reduce the severity of the
disease (Canna et al., 2017).
However, IL-1 is responsible for several signs and symptoms
of MAS. For example, fever and the increase in ferritin levels
are IL-1-mediated, since IL-18 does not cause fever (Gatti et al.,
2002; Robertson et al., 2006), does not induce prostaglandins (Lee
et al., 2004), and does not induce hepatic acute phase proteins
(Stuyt et al., 2005). It should also be noted that IL-1 induces
IL-18, and that this mechanism likely plays a critical role in
MAS. For example, IL-1 induces the release of constitutively
preformed IL-18 precursor from the endothelium (Pomerantz
et al., 2001). Elevated levels of IL-18 in MAS likely reflect
release from IL-1-activated endothelium, rather than myeloid
origin. IL-1-induced myocardial suppression is also mediated
by IL-18 (Pomerantz et al., 2001; Toldo et al., 2014). IL-1
mediates fever, hyperferritimia, coagulopathy, and production of
IL-18; IL-18 likely mediates hypersplenism, hypertriglyceridemia,
hypotension, and elevated IFNγ. With high levels of IL-18-
dependent IFNγ, there is macrophage activation in the bone
marrow and hemophagocytosis, which characterizes MAS.
Anakinra for MAS
Anakinra has primarily been used in MAS due to SoIJA and
occasionally to AOSD (Kelly and Ramanan, 2008; Miettunen
et al., 2012; Rajasekaran et al., 2014). Although most studies
describe favorable results, reports of efficacy are mixed, and
include some cases of SoJIA or AOSD who developed MAS while
receiving therapy with IL-1 blockade (Colafrancesco et al., 2017).
It is possible that development of MAS in these patients simply
reflects extreme severity or inadequate control of underlying
diseases. Indeed, increasing the dose of anakinra can result in
clinical improvement (Sonmez et al., 2018).
Hints of the efficacy of IL-1 blockade in MAS also come
from clinical experience with septic shock. Many years ago,
anakinra treatment was evaluated in three randomized, placebo-
controlled trials of patients with sepsis or septic shock. In nearly
2000 patients enrolled in these trials, anakinra did not reduce
overall all-cause mortality. However, recent re-analysis of data
from these original studies revealed that a significant benefit of
anakinra treatment could be identified in a subset of patients
exhibiting a strikingly inflammatory phenotype, which was highly
reminiscent of MAS and clinically characterized by cytopenia and
elevated ferritin and liver enzymes levels (Shakoory et al., 2016).
Behcet’s Disease
Behçet’s disease is a rare vasculitis of small- and medium-sized
vessels characterized by ocular and cutaneous inflammation,
oral and genital ulcers, gastrointestinal or brain vasculitis, and
hypercoagulable state. Ocular involvement may cause organ-
threatening uveitis and retinal vasculitis. Severe, steroid-resistant
disease responds to IL-1 blockers, which can afford dramatic and
sustained reversal of intraocular inflammation (Cantarini et al.,
2015a,b).
In an open-label pilot study of anti-IL-1β antibodies
(gevokizumab) in the treatment of acute eye inflammation, a
single dose prompted complete resolution of pan-uveitis and
restored normal vision within 4–21 days (Gul et al., 2012).
Systemic Vasculitides: Kawasaki
Disease, Takayasu Arteritis, Giant Cell
Arteritis
Kawasaki disease is one of the most common systemic
vasculitides and a leading cause of acquired heart disease in
children. It typically affects coronary arteries, and residual
vascular damage can cause complications later in life, including
myocardial infarctions. Classic treatment options include
intravenous immunoglobulin (IVIG) and aspirin. Of note, the
beneficial anti-inflammatory and therapeutic effects of IVIG
in several immune-mediated disorders include a reduction in
IL-1 production with an increase in IL-1Ra (Aukrust et al.,
1994). Consistently, reports on the efficacy of anakinra treatment
indicate that IL-1 plays a pivotal role in the development of
vascular damage in KD (Cohen et al., 2012; Dusser and Kone-
Paut, 2017; Blonz et al., 2018; Gamez-Gonzalez et al., 2018;
Kone-Paut et al., 2018). A prospective trial on anakinra in KD is
underway (NCT02179853).
Coronary and peripheral artery inflammation also
characterizes large vessel vasculitides Takayasu and giant
cell arteritis (Berti et al., 2015; De Luca et al., 2017; Cavalli
et al., 2018). Therapies for steroid- and DMARD-refractory
large vessel vasculitides are limited. Analysis of temporal artery
specimens from GCA patients revealed that IL-1 is highly
expressed in inflamed vessels (Hernandez-Rodriguez et al.,
2004): accordingly, anakinra treatment dampened systemic and
arterial inflammation in two cases refractory to conventional
treatment (Ly et al., 2013).
Histiocytic Disorders
Erdheim–Chester disease (ECD) is a rare form of non-
Langerhans histiocytosis, characterized by infiltration of foamy
macrophages into multiple tissues (Campochiaro et al., 2015).
The disease is typically sustained by activating mutations
along the mitogen-activated protein kinase (MAPK) or related
pathways in macrophages, which lead to cell activation and
consequent production of high levels of pro-inflammatory
cytokines and fibrosis of affected tissues (Cavalli et al., 2014;
Cangi et al., 2015; Pacini et al., 2018). Clinical manifestations
include bone pain, neurological symptoms, retroperitoneal
fibrosis, and congestive heart failure (Cavalli et al., 2013a,b;
Ferrero et al., 2016; Iurlo et al., 2016; Chiapparini et al.,
2018). Anakinra is effective in ameliorating skeletal, cardiac,
retroperitoneal, and systemic manifestations (Aouba et al., 2010;
Killu et al., 2013; Franconieri et al., 2016; Tomelleri et al., 2018),
thus substantiating the central role of macrophages in diseases
responsive to IL-1 blockade (Diamond et al., 2014; Berti et al.,
2017; Cavalli et al., 2017a). Interestingly, a traditional treatment
option for ECD, that is, alpha interferon (IFNα), may exert
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beneficial effects via induction of IL-1Ra (Tilg et al., 1993) and
inhibition of inflammasome activation (Guarda et al., 2011).
Modulation of the IL-1 pathway may indeed explain the efficacy
of IFNα in the management of ECD, as well as in a spectrum
of clinical conditions similarly characterized by the BRAFV600E
mutation and activation of the IL-1 pathway, including hairy cell
leukemia and melanoma.
Hearing Loss
Hearing Loss in Autoinflammatory Syndromes
Sensorineural deafness is a prominent characteristic of CAPS, a
spectrum of conditions caused by activating mutations in NLRP3
leading to deregulated release of active IL-1β (Aganna et al.,
2002), which are effectively treated with IL-1 blockade. The first
reports of reversal in sensorineural deafness with anakinra came
from patients with MWS, a CAPS subtype (Rynne et al., 2006);
several other reports followed (Gerard et al., 2007; Kitley et al.,
2010; Ahmadi et al., 2011; Klein and Horneff, 2011; Kuemmerle-
Deschner et al., 2011b,c, 2013; Eungdamrong et al., 2013; Stew
et al., 2013). This reversal in sensorineural deafness with anakinra
treatment delineated the unexpected concept that hearing loss
in autoinflammatory diseases is due to a reversible chronic
inflammatory response, rather than permanent loss of neuronal
function. Nevertheless, early treatment with anakinra is more
likely to be beneficial (Sibley et al., 2012). Patients with NOMID,
a more severe disease also part of the CAPS spectrum, also
benefit from anakinra treatment for hearing loss. In pediatric
patients with CAPS, early identification in childhood and early
anakinra treatment prevents or rescues sensorineural deafness
and hearing loss, and results in normal intellectual development
into adulthood (Rigante et al., 2006; Hedrich et al., 2008 #7023;
Sibley et al., 2012).
Anakinra in Autoimmune Hearing Loss
Sensorineural deafness also occurs in vasculitis and autoimmune
inner ear disease, and is clinically manifested as rapidly
progressive, often irreversible hearing loss. Treatment relies
on high-dose glucocorticoids, but many patients are refractory
or become unresponsive over time. In these refractory cases,
elevated IL-1β was demonstrated in the circulation and in
monocyte cultures (Pathak et al., 2011). In an open-label, single-
arm, phase I/II clinical trial of anakinra in corticosteroid-resistant
autoimmune inner ear disease, 10 patients received treatment for
12 weeks. Of these, seven obtained audiometric improvement,
paralleled by reduced IL-1β plasma levels (Vambutas et al., 2014).
Dry Eye Disease
Dry eye syndrome, or keratoconjunctivitis sicca, is a common,
multifactorial disorder of the eye characterized by deficient tear
production, excessive tear evaporation, or both. Meibomian
gland dysfunction is thought to be the leading cause of this
condition, which results in discomfort, visual disturbance, and
ocular surface damage. Topical administration of low-dose
(2.5%) anakinra proved effective in a randomized clinical trial of
75 dry eye disease patients, which achieved a significant reduction
in mean severity score and symptoms (Amparo et al., 2013). It is
tempting to envisage similarly favorable results in patients with
Sjögren and sicca syndrome.
Pulmonary Silicosis
Pulmonary silicosis is an occupational disease caused by
inhalation of silica crystals. These are not effectively cleared by
alveolar macrophages and induce a chronic inflammatory
response eventually leading to pulmonary fibrosis and
progressive respiratory insufficiency (Leung et al., 2012).
Since silica crystals activate the inflammasome and trigger
release of active IL-1β (Hornung et al., 2008), a study evaluated
anakinra treatment and documented progressive improvement
in respiratory symptoms and pulmonary inflammation in a
patient with pulmonary silicosis and severe respiratory failure
(Cavalli et al., 2015a).
Organ Transplant
Previous studies identified associations between levels of IL-1β
and IL-1Ra in serum and urine and negative graft outcome;
studies in experimental animals and observations in humans
also substantiated a possible protective effect of blocking IL-
1 after solid organ transplantation (reviewed in Mulders-
Manders et al., 2017). New evidence suggests that in patients
undergoing solid organ transplantation, IL-1 inhibition in
addition to standard immunosuppressive regimens may dampen
inflammation and protect against negative graft outcome.
Three patients undergoing renal transplantation were receiving
treatment with anakinra in the peri-operative and post-
operative period for underlying IL-1-driven autoinflammatory
diseases (AOSD, CAPS, and FMF, respectively). Kidney function
increased rapidly in all patients; anakinra was well tolerated and
safe with the exception of minor infections (Mulders-Manders
et al., 2017). The beneficial effects of treatment are likely due to
dampening of ischemia-reperfusion injury, which accompanies
renal transplantation and leads to release of IL-1 and to impaired
graft function.
ANAKINRA FOR CENTRAL NERVOUS
SYSTEM DISEASES
Neurologic complications observed in CAPS patients reveal the
effects of IL-1-mediated inflammation in the brain. Common
clinical manifestations include headache or migraine, sensory-
neural hearing loss, papilledema due to elevated intracranial
pressure, and mental impairment (Kitley et al., 2010). IL-1
blockade with anakinra or canakinumab reverses neurologic
inflammation and related symptoms, including mental and
hearing impairment (Lachmann et al., 2009; Goldbach-Mansky,
2011; Kuemmerle-Deschner et al., 2011a; Lepore et al., 2011;
Neven et al., 2011).
Anakinra Enters the Brain
The first evidence that anakinra administered peripherally
crossed the blood–brain barrier and reduced severity of a
disease primarily localized to the central nervous system came
from NOMID (Goldbach-Mansky et al., 2006). Specifically,
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12 children with NOMID were treated with 1–2 mg/kg of
subcutaneous anakinra daily. The median cerebrospinal fluid
(CSF) level of IL-1Ra was 211 pg/mL before treatment, but rose
to 1136 pg/mL after 3 months of treatment (Goldbach-Mansky
et al., 2006). These effects were associated with a remarkable
decrease in the severity of various NOMID manifestations,
including elevated intracranial pressure, leptomeningitis, and
neurosensorial hearing loss, as well as reduced CSF levels of IL-6.
Intravenous anakinra was also administered to patients with
subarachnoid hemorrhage due to aneurysmal rupture (Singh
et al., 2014), again in a placebo-controlled setting. Within 72 h
of the acute event, patients received a bolus infusion of 500 mg of
anakinra followed by a steady infusion of 10 mg/kg/h for 24 h. At
24 h, CSF levels of IL-6 were reduced in the anakinra compared
to the placebo group (Singh et al., 2014).
A related study investigated the dose regimen necessary
to obtain a CSF concentration of anakinra 100 ng/mL. This
concentration (100 ng/mL) was deemed neuro-protective based
on studies of rats subjected to brain ischemia (Clark et al.,
2008); as for human reference, this target concentration of
100 ng/mL is 100-fold greater than that in the CSF of
children receiving subcutaneous anakinra 100 mg daily for
3 months (Goldbach-Mansky et al., 2006). In this study,
patients with subarachnoid bleed received incremental doses
of intravenous anakinra (Galea et al., 2011): specifically, the
patients received a bolus dose of anakinra (100–500 mg) followed
by a 4-h infusion of anakinra from 1 to 10 mg/kg/h. Levels
of anakinra were monitored in plasma and CSF (collected
through a cerebral ventricular drain). A target CSF level of
100 ng/mL was achieved with the highest regimen (a bolus
of 500 mg followed by 4 h of anakinra at 10 mg/kg/h; Galea
et al., 2011; Ogungbenro et al., 2016). The authors concluded
that anakinra passively enters the brain in patients with a
subarachnoid hemorrhage: therefore, a high-dose regimen of
anakinra may reduce inflammation, infiltration of neutrophils,
and edema at the site of the lesion. In a subsequent randomized
study, patients with subarachnoid hemorrhage received anakinra
100 mg twice daily subcutaneously within 3 days of stroke
and for the following 21 days. Again, anakinra treatment
significantly reduced levels of inflammatory markers IL-6, CRP,
and fibrinogen. Although these studies were not powered to
determine clinical effects, scores of the Glasgow Outcome
Scale at 6 months were better, albeit not significantly, among
patients receiving anakinra. Whether dampening of IL-1-
mediated inflammation will result in improved neurological
outcomes remains to be determined in adequately powered,
randomized, placebo-controlled studies.
In a different study, intravenous anakinra was administered
to patients admitted to the hospital within 6 h of an acute
thrombotic stroke (Emsley et al., 2005). This trial included 34
patients and was randomized and placebo controlled; anakinra
was administered at a high dose of 2 mg/kg/h for 72 h, analogous
to inception trials of anakinra in septic shock. Compared to
placebo-treated controls, patients treated with anakinra had
lower IL-6, CRP, and neutrophil levels (Emsley et al., 2005).
Although the study was not powered for detecting significant
improvements in neurological outcomes, the subgroup of
patients with cortical infarcts receiving anakinra performed
better compared to the placebo group.
Additional evidence that anakinra crosses the blood brain
barrier and exerts anti-inflammatory effects in the brain comes
from studies of traumatic brain injury, a major cause of death
and disability worldwide, particularly in young persons. In
a randomized, open-label trial, 20 patients who had suffered
diffuse traumatic brain injury within the previous 24 h received
either anakinra 100 mg daily for 5 days or placebo. A central
microdialysis catheter was placed in each patient as part of
standard of care. Prior to administration of anakinra, the mean
level of IL-1Ra in the CSF was 78 pg/mL but rose to 138 pg/mL
12 h after the first dose (Helmy et al., 2014). In general,
inflammatory cytokines in the CSF were lower in patients treated
with anakinra; of these, macrophage-derived chemoattractant-
1 (MDC-1) was remarkably lower compared to patients treated
with the placebo (1.04 pg/mL in the anakinra group compared to
45.4 pg/mL in the placebo group; Helmy et al., 2014). The study
was not powered to evaluate clinical improvement, although the
marked decrease in CSF levels of cytokines and MDC-1 argue in
favor of beneficial anti-inflammatory effects.
Epilepsy
Although IL-1α is found in brain astrocytes and microglia,
available data point at IL-1β as the main contributor to epileptic
seizures (Vezzani et al., 2011). Several studies have focused on
febrile seizures since these are among the most common type
of seizure activity. Using an animal model for febrile seizures,
an agonist role for IL-1β and an antagonist role for endogenous
IL-1Ra in the hippocampus have been reported (Heida et al.,
2009). Other studies examined circulating cytokines in patients
with recurrent seizures, and revealed elevated levels of IL-6 and
IL-1Ra in the post-acute period (Uludag et al., 2013). In one
study, high levels of IL-1β were also observed during acute
episodes of recurrent temporal lobe epilepsy (Uludag et al., 2015).
Some studies have reported polymorphisms in IL-1α, IL-1β, and
IL-1Ra in subjects who develop epilepsy as adults (Kanemoto
et al., 2000; Haspolat et al., 2005; Nakayama and Arinami, 2006;
Serdaroglu et al., 2009; Chou et al., 2010). In experimental
animals, suppression of peripheral IL-1-mediated inflammation
reduces the severity of status epilepticus (Marchi et al., 2009).
Anakinra has been administered to a young patient with
a severe seizure disorder termed febrile infection-related
epilepsy syndrome (FIRES; Hirsch et al., 2018). This syndrome,
which often follows an infectious encephalopathy, has a high
mortality rate and few treatment options. This patient had
recurrent seizures each day, which progressively decreased in
frequency and eventually ceased while being treated with daily
subcutaneous anakinra (Kenney-Jung et al., 2016). This was
mirrored by a decrease in CSF pro-inflammatory cytokines.
When anakinra was stopped, seizures resumed only to decrease
again upon restarting. A subsequent study confirmed the
favorable outcome with anakinra described in this report.
Anakinra was administered to five children with FIRES and
refractory status epilepticus beginning shortly after a febrile
illness. All had received anti-epileptic drugs (AEDs, ranging from
two to six different medications), had required anesthetics for
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seizure control, and had received treatment with corticosteroids
and IVIG; three underwent plasmapheresis. Anakinra was
initiated on day 12–32 of illness at a dose ranging from 3
to 7 mg/kg/day, and led to rapid and remarkable clinical
improvement in all but one patient. Specifically, seizure count
in the week prior to anakinra initiation ranged from 8 to 170,
but dropped to 0–12 after 1 week of anakinra treatment and
to 0–7 after 4 weeks of treatment. Two patients had increased
seizure burden upon anakinra weaning or discontinuation, again
substantiating the role of IL-1 in seizure disorder (Shukla et al.,
2018). In another study, an adolescent female with signs of
persistent systemic inflammation and epilepsy unresponsive to
multiple AEDs also promptly responded to anakinra (DeSena
et al., 2018).
SAFETY OF IL-1 BLOCKADE WITH
ANAKINRA
Impaired host defense against pathogens is a concern for
cytokine-blocking agents. In patients treated with biologics,
particularly TNFα blocking therapies, there is an increased risk
of several opportunistic infections, similar to those observed in
immunosuppressed persons. Host defense against opportunistic
organisms as well as common bacterial infections have since
become a major concern for all anti-cytokine agents because
of the indolent and dangerous nature of these infections.
For example, reactivation of latent M. tuberculosis in patients
receiving anti-TNFα therapies can be 25 times higher than
in untreated persons (Solovic et al., 2011) and is often in
the disseminated form, similar to that observed in HIV-
1 infected patients. M. tuberculosis also occurs in patients
treated with TNFα blockers without evidence of prior exposure
to the organism. Despite screening for previous exposure to
M. tuberculosis before beginning any anti-cytokine treatment,
reactivation continues to occur and can be as high as 9.3% (Chiu
et al., 2011).
As with all biologic agents, an increase in infection frequency
has been reported for anakinra. Nevertheless, in comparison
to other biologic agents, anakinra has an unparalleled safety
benefit deriving from short half-life and effect duration, and has
demonstrated a remarkable record of safety (Fleischmann et al.,
2006; Mertens and Singh, 2009b). Since introduction in 2002, it
is estimated that over 150,000 patients have received anakinra,
some treated daily for over 10 years. Opportunistic infections
in patients treated with anakinra are rare (Fleischmann et al.,
2003), including in populations at high risk for reactivation of
M. tuberculosis infections (Bresnihan et al., 1998; Lopalco et al.,
2016a,b). There is a single case report of a 77-year-old man
with severe RA and a history of pulmonary tuberculosis who
developed a reactivation 23 months after starting anakinra (Settas
et al., 2007).
In addition, a large number of animal studies including
primates subjected to live bacteria inoculum demonstrated
greater survival in infected animals treated with anakinra
compared to vehicle. In humans, anakinra has been administered
to patients with active infections (Hennig et al., 2010; van de
Veerdonk et al., 2011), and in over 2000 patients in trials
of sepsis and septic shock without any increase in mortality
despite exceedingly high dosing (30-fold higher than the current
approved dose of 100 mg/day; Dinarello et al., 2012). Other
safety examples include hidradenitis suppurativa, in which
anakinra treatment resolves inflammation of Staphylococcus
aureus-infected apocrine glands (Braun-Falco et al., 2011; Hsiao
et al., 2011; Zarchi et al., 2013; Tzanetakou et al., 2016), and
chronic granulomatous disease, an inherited condition with
recurrent bouts of infections with Gram-positive and Gram-
negative bacteria as well as fungi (van de Veerdonk et al.,
2011): in both conditions, treatment with anakinra reduces
the severity of inflammation without increasing the infection
burden.
During controlled trials of anakinra, there were more viral-
type upper airway infections compared to placebo-treated
patients, as for most other biologics. There are two spurious
reports of anakinra-related hepatotoxicity in patients with AOSD;
however, withdrawal of anakinra restored normal liver function.
Of note, there are several reports of the safety of increasing the
dose of anakinra to 200 mg/day or above (Vitale et al., 2016;
Colafrancesco et al., 2017; Grayson et al., 2017).
Subcutaneous administrations of anakinra often cause
injection site reactions. Albeit uncomfortable due to the need
for daily injections, these usually resolve within 2–3 weeks of
treatment initiation. A fraction of patients receiving treatment
with anakinra can develop antibodies against the drug (Cohen
et al., 2002; Ilowite et al., 2009). As with other biologic agents, the
potential for adverse effects including hypersensitivity reactions
or aplasia should be carefully monitored. Conversely, these
antibodies are usually non-neutralizing and do not decrease the
biologic effectiveness of anakinra, nor they appear to be linked to
the development of injection site reaction.
Interleukin-1 injected into humans at doses as low as 3 ng/kg
induce neutrophil mobilization from the bone marrow and
neutrophilia (Dinarello, 1996; Ogilvie et al., 1996). Hence, most
patients with IL-1-mediated conditions exhibit neutrophilia as
a hematological manifestation of their disease. A reduction
in circulating neutrophils upon anakinra administration can
be observed and often heralds a clinical response; sustained
neutropenia is not typically observed, but neutrophil levels
occasionally fall below the normal range, only to rise rapidly upon
cessation of treatment (Cavalli and Dinarello, 2015).
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